Patents Expiring in July 2031
✉ Email this page to a colleague
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Azurity | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-001 | Dec 20, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF HYPERTENSION | ||||
Azurity | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-002 | Dec 20, 2011 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF HYPERTENSION | ||||
Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | ||||
Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE | ||||
Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |